Kiran Mazumdar-Shaw is reportedly choosing her niece, Claire Mazumdar, as her successor at Biocon, according to reports from Times of India and Business Standard. Claire Mazumdar, 37, is currently the founder and chief executive of Bicara Therapeutics. Bicara Therapeutics is described in the reports as having been incubated by Biocon before later being listed on NASDAQ. Times of India also states that Bicara Therapeutics went public in 2024 and has a market valuation of more than $1.6 billion. Business Standard adds that a gradual transition is planned, indicating that Mazumdar-Shaw’s departure from leadership is expected to be phased rather than immediate. Together, the sources frame the move as an internal succession plan that places leadership within the broader family and business ecosystem surrounding Biocon and its incubated ventures. The reports do not provide further details on timing, specific roles, or formal approval processes, but they consistently identify Claire Mazumdar as the designated successor and outline her leadership position at Bicara Therapeutics.